Certara Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $104.6 million, up 10% year-over-year.

Adjusted EBITDA: $35.2 million, with a margin of 34%.

Bookings: $96.6 million, a 1% increase year-over-year; trailing 12-month bookings at $471.4 million, up 12%.

Software Revenue: $43.8 million, a 22% increase; organic growth at 6%.

Services Revenue: $60.8 million, up 3% year-over-year.

Net Income: $1.5 million, compared to a net loss of $1.4 million in Q3 2024.

Adjusted EPS: $0.14, up from $0.13 in the prior year.

2Strategic Updates and Business Highlights

Continued investment in R&D, increasing to 10% of revenue, with a 24% year-over-year growth in R&D spending.

Successful product launches, including Pinnacle 21 Enterprise, Phoenix Cloud, and CertaraIQ, which are expected to enhance software growth.

Positive reception of new products, particularly in the QSP (Quantitative Systems Pharmacology) area, which is becoming a key growth driver.

The Chemaxon acquisition is performing well, contributing $5.6 million in revenue and on track for corporate average margins by year-end.

3Forward Guidance and Outlook

Revenue guidance narrowed to $415 million to $420 million for 2025, reflecting 8% to 9% growth.

Adjusted EBITDA margin guidance raised to around 32%.

Adjusted EPS expected in the range of $0.45 to $0.47.

Anticipation of continued cautious spending behavior among Tier 1 customers into Q4, impacting bookings.

4Bad News, Challenges, or Points of Concern

Bookings Decline: Notable slowdown in Tier 1 services bookings, with cautious spending and delayed decision-making affecting revenue.

Regulatory Services: Decline in regulatory services bookings, with some customers facing hesitancy in decision-making.

Market Conditions: Ongoing macroeconomic uncertainties affecting large pharma customers, leading to a cautious outlook for 2026.

Organic Bookings: Excluding Chemaxon, organic bookings declined by 4% year-over-year.

5Notable Q&A Insights

Management acknowledged a slowdown in decision-making among Tier 1 customers, with expectations for continued hesitancy into Q4.

There is cautious optimism regarding a stabilizing macro environment, which could positively impact growth in 2026.

The company is seeing strong performance in Tier 2 and Tier 3 services, contrasting with challenges faced by Tier 1 customers.

Concerns about potential impacts from government shutdowns on FDA operations were addressed, with management expressing confidence in a resolution that would not significantly affect operations. Overall, Certara's Q3 2025 results reflect solid revenue growth and strategic advancements, though challenges in Tier 1 customer spending and regulatory services present notable headwinds as the company looks toward 2026.